Finoriq research workspace
Amphastar Pharmaceuticals, Inc. (AMPH) SEC Filings & Filing Highlights
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets. Review AMPH SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
- Company
- Amphastar Pharmaceuticals, Inc. (AMPH)
- Ticker
- AMPH
- Market Cap
- $876.6M
- Latest Price
- $19.88
- Industry
- Biotech & Pharma
Amphastar Pharmaceuticals, Inc. (AMPH) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Amphastar Pharmaceuticals, Inc. (AMPH).
| Event | Form | Date |
|---|---|---|
| Amphastar Pharmaceuticals, Inc.: Corporate updateOn July 2, 2026, International Medication Systems, Limited (“IMS”), a subsidiary of the Company, received a warning letter (the "Warning Le... | 8-K8.01 | 2026-07-08 |
| To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public a...The stockholders of the Company voted on the following items at the Annual Meeting, each of which is described in more detail in the Compan... | 8-K5.07 | 2026-06-03 |
| Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 | 8-K2.02 | 2026-05-07 |
| The timing and actual number of shares repurchased will depend on a variety of factors includin...On March 12, 2026, the Company’s Board of Directors authorized a $50 million increase to the Company’s share buyback program, which is expe... | 8-K8.01 | 2026-03-16 |
| On March 3, 2026 (the “Effective Date”), Amphastar Pharmaceuticals, Inc. (“Amphastar” or, the... On March 3, 2026 (the “Effective Date”), Amphastar Pharmaceuticals, Inc. (“Amphastar” or, the “Company”), entered into executive employme... | 8-K5.02 | 2026-03-06 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.